Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses ...

How Eli Lilly Is Thinning Out the Competition. By Natalie Forbes – Aug 17, 2022 at 10:00AM Key Points. Latest earnings ... More potential in weight loss ...

Eli Lilly's weighted average cost of capital is 7.08%, with an equity weight of 96.35% and a debt weight of 3.65%. Equity costs 7.27% and debt costs 2.64% after tax.

Lilly’s stock soared after the company announced a successful trial of its new weight loss drug. Google Market These medications mimic a hormone called glucagon-like peptide-1, which regulates ...

FDA approves weight loss drug Zepbound, joining Ozempic and Wegovy in market 04:47. Eli Lilly has a message for people who are taking prescription medications developed for patients with Type 2 ...

In a groundbreaking move, Eli Lilly LLY is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight. What Happened: Dave Ricks, CEO of Eli ...

Eli Lilly (LLY 2.32%) is a leader in one of the pharmaceutical industry's highest-growth markets: weight loss drugs. This market may increase by 16x from today's size to reach $100 billion by the ...

An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss seen yet ...